Publicaciones (59) Publicaciones en las que ha participado algún/a investigador/a

2018

  1. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER + breast cancer

    Nature Cell Biology, Vol. 20, Núm. 2, pp. 211-221

  2. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)

    Annals of Oncology, Vol. 29, Núm. 8, pp. 1634-1657

  3. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

    EMBO Molecular Medicine, Vol. 10, Núm. 12

  4. A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: The METTEN study

    Oncotarget, Vol. 9, Núm. 86, pp. 35687-35704

  5. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade

    Annals of Oncology, Vol. 29, Núm. 1, pp. 170-177

  6. A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: Final results of the IBCSG 42-12/BIG 2-12 SNAP trial

    Annals of Oncology, Vol. 29, Núm. 3, pp. 661-668

  7. Anastomosis microquirúrgica

    Cirugía oral y maxilofacial: atlas de procedimientos y técnicas quirúrgicas (Editorial Médica Panamericana), pp. 891-896

  8. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial

    The Lancet Oncology, Vol. 19, Núm. 6, pp. 812-824

  9. Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

    Clinical and Translational Oncology, Vol. 20, Núm. 7, pp. 815-826

  10. Breast cancer in 2017: Spurring science, marking progress, and influencing history

    Nature Reviews Clinical Oncology, Vol. 15, Núm. 2, pp. 79-80

  11. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2

    European Journal of Cancer, Vol. 103, pp. 147-154

  12. CXCR4 antagonists for treatment of breast cancer

    Oncotarget

  13. Change in topoisomerase 1–positive circulating tumor cells affects overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol

    Clinical Cancer Research, Vol. 24, Núm. 14, pp. 3348-3357

  14. Complete resolution of dysphagia after sequential Polyflex™ stenting in a case of recurrent anastomotic stenosis in an adult with congenital esophageal atresia

    Revista Española de Enfermedades Digestivas, Vol. 110, Núm. 12, pp. 826-829

  15. Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Revista Espanola de Patologia

  16. Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology (Clinical and Translational Oncology, (2018), 20, 7, (815-826), 10.1007/s12094-017-1800-5)

    Clinical and Translational Oncology

  17. Corrigendum: Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: A proof-of-principle (Annals of Oncology (2014) 25 (1729–1735) DOI: 10.1093/annonc/mdu239)

    Annals of Oncology

  18. Corrigendum: Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab [Ann Oncol., 28, (2017) (761-768)] DOI: 10.1093/annonc/mdw695

    Annals of Oncology

  19. Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

    Melanoma Research, Vol. 28, Núm. 3, pp. 195-203

  20. El urólogo del futuro y las nuevas tecnologías

    Archivos Espanoles de Urologia, Vol. 71, Núm. 1, pp. 142-149